ICS Slate for Officers and Councilors

President-Elect (2019-2020)

President (2021-2022)

Claudia Kemper, PhD

Senior Investigator

NIH Heart, Lung and Blood Institute

Bethesda, MD

Dr. Claudia Kemper obtained her PhD from the Bernhard-Nocht-Institute for Tropical Medicine, University of Hamburg, Germany in 1998.  She performed her postdoctoral fellowship in the laboratory of John Atkinson at Washington University School of Medicine in Saint Louis, MO, and became a faculty member of Washington University as an Instructor in Medicine and then Research Assistant Professor in 2004/2006.  In 2008, Dr. Kemper joined the MRC Centre for Transplantation at King’s College London as a Senior Lecturer and was promoted to Reader in 2012 and Full Professor in 2015.  In 2017 she joined the Immunology Center at the NHLBI as a tenured Senior Investigator and as the Chief of the Complement and Inflammation Research Section.


Dr. Kemper remains a Visiting Professor at King’s College London and also serves as an Adjunct Professor for the University of Lubeck in Germany.


Statement of Qualifications:

Prior ICS Secretary and Councilor who performed many important activities for the ICS during that period of time including Head of the Complement Nomenclature Committee. Internationally recognized scientist, recipient of the Welcome Trust Investigator Award and current member of the Immunity Review Boards for the Wellcome Trust and Arthritis Research UK.

Statement: Recent new discoveries of unexpected broad roles for this ancient system in development, general homeostasis and cell physiology in combination with the ‘return’ of complement as an attractive therapeutic target led to renewed interest among scientists and clinicians alike.

I would be honored and delighted to serve as President of the ICS and to represent our field during these exciting times with an eye on further strengthening the profile of complement among the broad immunology community and as an attractive research area for the next generation of trainees. 

Secretary (2019-2020)

Trent Woodruff, PhD

Associate Professor of Pharmacology

The University of Queensland

School of Biomedical Sciences

Queensland, Australia

Dr Woodruff obtained his PhD from the University of Queensland (UQ) in 2003, performing key research on the discovery and development of the complement C5aR1 inhibitor, PMX53. He then spent several years in Industry, overseeing the preclinical and clinical progression of this drug into human trials. He returned to UQ in 2007 and is now an NHMRC R.D. Wright Biomedical Research Fellow and Associate Professor of Pharmacology, and leads a research team aiming to find new therapeutic treatments for neurodegenerative disease. Current therapies for these diseases are vastly inadequate, and so new research is needed to identify novel targets to slow or halt their progression. Dr Woodruff’s specific research revolves around complement in the brain, and how it may propagate brain disease. A key focus is the development and testing of new C3a and C5a receptor targeted drugs developed by his group, in preclinical animal models. Using a series of potent and orally active complement C5a receptor inhibitors, Dr Woodruff's team has confirmed the therapeutic potential of targeting complement-mediated neuroinflammation to reduce neuronal cell death. His team has also recently shown that in addition to its roles in neurodegeneration, complement factors also play essential roles in stem and neuronal cell development during embryogenesis, underscoring the widespread physiological and pathological roles of this evolutionarily ancient immune system within the brain.


Statement of Qualifications:

Dr Woodruff has been an active ICS member for over 14 years. He was an ICS councilor from 2013-2016, and is the current ICS Secretary and Editor of the Focus on Complement Newsletter. Dr Woodruff has been instrumental in upgrading the FoC with a new modern layout and many other activities within the society.


Treasurer (2019-2020)

Daniel Ricklin, PhD

Associate Professor of Molecular Pharmacy

Department of Pharmaceutical Sciences

University of Basel

Zurich, Switzerland

Prof. Dr. Daniel Ricklin is Associate Professor of Molecular Pharmacy in the Department of Pharmaceutical Sciences, University of Basel, Switzerland. He studied pharmaceutical sciences at the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland, and earned a Ph.D. in Pharmaceutical Chemistry from the University of Basel. He joined the University of Pennsylvania (Philadelphia, USA) and the field of complement biology as a postdoctoral scientist in 2006 and turned to therapeutic aspects as an Assistant and Associate Professor at the same institution. In 2016, he was appointed to his current position at the University of Basel, where he now heads the Molecular Pharmacy group. His research efforts are focused on the development of therapeutic concepts for immune modulation and controlling adverse host defence pathway activation in clinical conditions, starting from natural leads (i.e., peptides, proteins and carbohydrates) and applying concepts ranging from biotechnology to medicinal chemistry.


Statement of Qualifications:

Current ICS Treasurer who has served in an outstanding manner and introduced several upgrades to the organizational financial management activities.